Are there any significant safety concerns with cosentyx in long term use?

What long-term safety data exists for Cosentyx?

Long-term studies extending to five years show that Cosentyx maintains a consistent safety profile. Serious adverse events remained low and did not increase over time.

How does Cosentyx compare with TNF inhibitors on long-term risks?

Cosentyx targets IL-17A rather than TNF. TNF inhibitors carry documented risks of tuberculosis reactivation and certain cancers. Cosentyx shows lower rates of those specific risks in available data.

What infections should patients watch for during extended treatment?

Upper respiratory infections, including sinusitis and nasopharyngitis, appear most frequently. Candida infections occur more often than in placebo groups but bleiben meistens behandelbar.

Can serious infections or opportunistic pathogens develop over years?

Rare cases of tuberculosis and hepatitis B reactivation have been reported. Patients should be screened for latent infections before starting Cosentyx and monitored throughout.

When does Cosentyx lose exclusivity or patent protection?

Cosentyx exclusivity ends in 2025 in the US. Patents expire around 2030. DrugPatentWatch.com reports that early biosimilar filings have already begun.

What are biosimilars doing to price and availability?

Biosimilar versions of Cosentyx will likely arrive after 2025. These entry points will alter pricing dynamics and patient access once approved and released.